NPM1 and acute myeloid leukemia: While the patient's initial bone marrow showed only 6% blasts, molecular testing revealed an NPM1 mutation—an abnormality that, under the WHO 5th edition (2022) [7], is sufficient to establish a diagnosis of “AML with mutated NPM1,” regardless of blast percentage.